Avadel Pharmaceuticals plc

NasdaqGM AVDL

Avadel Pharmaceuticals plc Market Capitalization on January 14, 2025: USD 775.71 M

Avadel Pharmaceuticals plc Market Capitalization is USD 775.71 M on January 14, 2025, a -43.18% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Avadel Pharmaceuticals plc 52-week high Market Capitalization is USD 1.81 B on May 03, 2024, which is 133.43% above the current Market Capitalization.
Avadel Pharmaceuticals plc 52-week low Market Capitalization is USD 753.55 M on January 13, 2025, which is -2.86% below the current Market Capitalization.
Avadel Pharmaceuticals plc average Market Capitalization for the last 52 weeks is USD 1.38 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: AVDL

Avadel Pharmaceuticals plc

CEO	Mr. Gregory J. Divis Jr.
IPO Date	June 7, 1996
Location	Ireland
Headquarters	10 Earlsfort Terrace
Employees	154
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Key trends

Past 5 years